Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma

被引:49
|
作者
Rintala, M [1 ]
Inki, P
Klemi, P
Jalkanen, M
Grénman, S
机构
[1] Univ Turku, Cent Hosp, Dept Obstet & Gynecol, FIN-20520 Turku, Finland
[2] Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland
[3] Turku Univ, Ctr Biotechnol, Turku, Finland
[4] Abo Akad Univ, Turku, Finland
关键词
syndecan-1; prognosis; clinical outcome; cervical carcinoma;
D O I
10.1006/gyno.1999.5595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The expression of syndecan-1, a cell surface heparan sulfate proteoglycan, is reduced during malignant transformation of squamous cells. Studies on squamous cell carcinoma of the head and neck have shown that syndecan-1-positive tumors are associated with longer overall and recurrence-free survival. The purpose of this study was to analyze syndecan-1 expression in invasive cervical carcinoma and to examine the association of syndecan-1 expression with prognostic factors and overall survival. Methods. The study population consisted of 124 patients treated for primary invasive carcinoma of the uterine cervix at the Turku University Central Hospital during the years 1970-1988. The material consisted of 102 (82.3%) squamous cell carcinomas, 16 (12.9%) adenocarcinomas and 1 (0.8%) adenosquamous carcinoma, 1(0.8%) small cell carcinoma, 1 (0.8%) adenoid basal carcinoma, 1 (0.8%) carcinosarcoma, and 2 (1.6%) unclassified cervical carcinomas. Syndecan-1 expression was determined on paraffin-embedded tissue blocks using a human syndecan-1-specific monoclonal antibody B-B4 and immunohistochemistry. The expression of syndecan-1 was classified according to staining intensity as well as the percentage of positively stained tumor cells. Results. Staining intensity was strong in 44 (36%) samples, while 24 (19%) specimens remained syndecan-1-negative. In 49 (40%) samples, the percentage of syndecan-1-positive cells was greater than or equal to 90%. Syndecan-1 expression, as determined by greater than or equal to 50% positively stained tumor cells, was associated with the grade of differentiation (P = 0.03) and squamous histology (P < 0.001), but was not associated with clinical stage (P = 0.16) or disease-free survival (P = 0.86). Age (P = 0.003) and clinical stage (P < 0.001) were significant prognostic factors, but syndecan-1 expression determined neither by percentage of positively stained tumor cells nor by staining intensity was associated with the outcome. Conclusions. In cervical carcinoma syndecan-1 is associated with histological differentiation grade and squamous histology, but does not predict clinical outcome. (C) 1999 Academic Press.
引用
收藏
页码:372 / 378
页数:7
相关论文
共 50 条
  • [41] Suppression of epithelial syndecan-1 expression by tumor necrosis factor-A.
    Day, R
    Mitchell, T
    Knight, S
    Forbes, A
    GASTROENTEROLOGY, 2000, 118 (04) : A806 - A806
  • [42] Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes
    Kakutani, Yoshinori
    Morioka, Tomoaki
    Yamazaki, Yuko
    Ochi, Akinobu
    Fukumoto, Shinya
    Shoji, Tetsuo
    Emoto, Masanori
    DIABETES & VASCULAR DISEASE RESEARCH, 2024, 21 (04):
  • [43] Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence
    Day, RM
    Hao, XP
    Ilyas, M
    Daszak, P
    Talbot, IC
    Forbes, A
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1999, 434 (02): : 121 - 125
  • [44] SYNDECAN-1 IN DECOMPENSATED HEART FAILURE: ASSOCIATION WITH RENAL FUNCTION AND MORTALITY
    de Oliveira Neves, Fernanda Macedo
    Leite, Tacyano Tavares
    Meneses, Gdayllon Cavalcante
    Araujo De Souza, Nazareth Herminia
    Costa Martins, Alice Maria
    Parahyba, Marcelo Coelho
    Bayas Queiroz, Rafaela Elizabeth
    Liborio, Alexandre
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 102 - 102
  • [45] Association of Preoperative and Postoperative Plasma Syndecan-1 and Colorectal Cancer Outcome
    Tanaka, Hidenori
    Hayashi, Hirokatsu
    Tomita, Hiroyuki
    Tokumaru, Yoshihisa
    Fukada, Masahiro
    Tajima, Jesse yu
    Yokoi, Ryoma
    Tsuchiya, Hiroshi
    Kuno, Masashi
    Sato, Yuta
    Yasufuku, Itaru
    Asai, Ryuichi
    Mori, Ryutaro
    Tanaka, Yoshihiro
    Okumura, Naoki
    Futamura, Manabu
    Matsuhashi, Nobuhisa
    ANTICANCER RESEARCH, 2024, 44 (04) : 1611 - 1618
  • [46] Suppression of syndecan-1 expression tumor necrosis factor-alpha
    Kainulainen, V
    Nelimarkka, L
    Jarvelainen, H
    Laato, M
    Jalkanen, M
    Elenius, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (31) : 18759 - 18766
  • [47] Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma
    Li, Hai-Gang
    Xie, De-Rong
    Shen, Xi-Ming
    Li, Hong-Hao
    Zeng, Hong
    Zeng, Yun-Jie
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (10) : 1445 - 1451
  • [48] Syndecan-1 expression has prognostic significance in head and neck carcinoma
    A Anttonen
    M Kajanti
    P Heikkilä
    M Jalkanen
    H Joensuu
    British Journal of Cancer, 1999, 79 : 558 - 564
  • [49] Endotheliopathy of trauma in children: The association of syndecan-1 with injury and poor outcomes
    Morgan, Katrina M.
    Abou-Khalil, Elissa
    Gaines, Barbara A.
    Leeper, Christine M.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2024, 96 (04): : 566 - 572
  • [50] Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil
    Sung Hak Lee
    Eun Ji Choi
    Min Sik Kim
    Jun Wook Park
    Youn Soo Lee
    Su Young Kim
    Chang Suk Kang
    International Journal of Clinical Oncology, 2014, 19 : 247 - 253